(IPCI) 5 Drugs under review by FDA (Mcap 47 M )= MULTIBAGGER

[BiotechMaster]

This Unknown low float Stock awaiting 5 FDA approvals and will rise to 7 by year end

Par Pharma (PRX) is the second largest Shareholder and Marketing Partner for Focalin which will be approved soon .

Market Cap of 47 Mil is really a BIG JOKE .They have enough cash to run their Company into profitable business .


I think $15++ is very realistic for 2011 .This Stock is a MUST for those who likes Biotech . GL


Intellipharmaceutics (IPCI)

Market Cap: 47 M
Cash: 13 M
Price: 2.97 $

Shares Out: 15.9 M.. ( 8 Million shares held by CEO)


Monster Pipeline
Intellipharmaceutics - Pipeline


New Presentation ..CHECK IT OUT !!!
http://www.intellipharmaceutics.com/...%20website.pdf


Intellipharmaceutics Submits 4th ANDA in 12 Months
Intellipharmaceutics Submits 4th ANDA in 12 Months - The ProActive Network - pitchengine.com


Great Article ..A must READ
No News is Good News for IntelliPharmaCeutics International Inc. (IPCI) - International Business Times


Another great Article
Bio Tuesday's Instablog - Seeking Alpha


Intellipharmaceutics now has five ANDAs awaiting FDA approval with reported sales for branded and generic versions of these products being approximately $8 billion in 2010. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.


Intellipharmaceutics' development milestones for 2011 include the following:

Obtain FDA approval of our generic version of Focalin XR(R)

Have two additional ANDA applications accepted for filing by FDA

Establish at least one additional development/marketing alliance

Complete manufacturing of clinical batches of Rexista(TM) oxycodone

Initiate Phase I studies using clinical batches of Rexista(TM)oxycodone

Schedule a pre-IND meeting with FDA to discuss Rexista(TM) oxycodone clinical development plan

[BiotechMaster]

I like no i LOVE this stock you have the huge opportunity to Buy IPCI at a Ridiculous low price . IPCI will move over 10++ dollar in the coming months . Again perfect time to Buy . Best Luck


Emerging Biotech Titan Loaded With Catalysts
1/21/2011 10:04:33 AM - BSR

Jan 21, 2011 (ACCESSWIRE via COMTEX News Network) --

Dr. Isa Odidi of Intellipharmaceutics (Nasdaq:IPCI) (TSX:I) is easily one of the sector's genius drug delivery innovators. While he was at Biovail, Odidi was performing drug alchemy with formulations that mimicked several hard-to-manufacture generic versions of expensive drugs- among them, Pfizer's (NYSE:PFE) Procardia XL, Bayer's (BAYRY.PK) Adalat CC, and Novartis' (NYSE:NVS) Voltaren XR. While serving as the company's Vice President of Research of Drug Development and New Technologies he helped grow Biovail through its adolescence.

As difficult as the scientific process was, the business plan was simple. Odidi and his team worked out the chemical composition to develop the drugs and pushed their versions through the regulatory process at the U.S. Food and Drug Administration. Once approved, the company licensed the drugs to different companies and collected royalties. While Odidi perfected his science and learned to navigate the FDA process, Biovail grew into a 10+billion market cap company.

You'd never notice him if you passed the Nigerian-born CEO on the street. Odidi is a quiet man whose demeanor and smile tend to understate his achievements and brilliance. His work has been cited in textbooks, scientific and medical papers and countless articles, but it was his work at Biovail that caught the attention of Wall Street after he first founded Intellipharmaceutics as a private company with his wife and colleague, Dr. Amina Odidi (an accomplished formulator and scientist who some often refer to as the company's Secret Weapon), in 1998.

Several financeers and investors with an eye for developing publicly traded companies recognized that Odidi and his unique talents as a master formulator might be worth a bit more than a paycheck- perhaps billions more. Through a carefully crafted reverse-merger in 2009, they helped take the company public and now, after careful incubation and lab work, it appears their bet on Odidi is about to pay off in multiple ways.

"We looked at what was happening in the generic space and we thought it was crowded by people who were doing things that were easy to do," explains Odidi when interviewed about the birth of his own company. "And so we tried to find a new niche where we could be competitive."

That niche was targeted and controlled released drugs using a proprietary Hypermatrix technology.

"As a result we are going after very difficult to make products," explains Odidi. "And the reason we chose to go this route is there are not many competitors playing in this field."

While most drug delivery companies deal in three-dimensions, Odidi decided to expand his vision and approach to drug composition by introducing a fourth and fifth dimension: space and time. "After all, we are in the time release business, so we should be looking at how to control time," says Odidi.

The result is what Odidi calls "super generics"- very good copies of drugs that are about to come off-patent and aim to make the original drug formulation better. According to Odidi, the technology allows him to deliver any active pharmaceutical ingredient to the body in the right amount at the right time.

As a result, Intellipharmaceutics has now filed approximately $6 billion of generic controlled released drugs with the FDA to date.

In anticipation of several key events, biotech investors have begun to buy up whatever shares they can get. Since we highlighted the company to our subscribers days ago, shares have nearly doubled and they look to go much higher for one simple reason. The float of available shares is nearly non-existent and those who have managed to purchase shares are simply not letting them go. The result is a developing "load and lock" investment play not unlike the one we saw when shares of a bankrupt Vermillion (Nasdaq:VRML) go from pennies to over $30 per share based on a single catalyst event- an FDA approval last year.

If you look under the hood, IPCI has a nearly identical number of shares outstanding and a growing number of hands that are buying as many shares as they can with both hands as they eyeball a list of multiple drug candidates and a stream of anticipated 2011 events that may fast track the young company into a generics powerhouse:

Pending approval of Dexmethylphenidate XR, a generic version of the marketed Novartis drug Focalin XR®, which IPCI partnered with Par Pharmaceutical. The drug is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA). Because the Generic Division of the FDA does not issue PDUFA action dates, the timing for a decision on the company's filing for the drug is not listed on biotech catalyst calendars. Savvy speculators have started placing their bets, nonetheless. The patent litigation designed to slow the approval process was paid for by Par and settled last March (at the time, the stock ran from approximately $1.50 to $5 on news of the settlement. Today the stock is starting to break out beyond those previous highs).

Licensing deal for Effexor- a $3.8 billion brand sales drug that was developed by Wyeth and subsequently acquired by Pfizer is used in the treatment of major depressive disorders. The FDA accepted IPCI's abbreviated new drug application (ANDA) last May and credible sources tell ************* that several companies are interested in licensing the generic as they believe they can capture a healthy share of the market. Conservative estimates place that share at $600 million with potential royalty revenues to IPCI of $30 to $120 million.

Licensing deal for Protonix- a $1.8 billion brand sales drug that is indicated for conditions associated with GERD (i.e. ulcers). Just weeks ago, the company notified the FDA that it has not received notification, as provided for under the Hatch-Waxman Act, of any patent infringement proceedings by the brand owner, Wyeth Pharmaceuticals, Inc., a wholly-owned subsidiary of Pfizer, Inc. Investors now know that Intellipharmaceutics will not be subject to the automatic 30-month stay of FDA approval to market the product and that has potential suitors swirling to make a deal which could net them an estimated $450 in sales with potential royalty revenues to IPCI of $22.5 to $90 million.

Investors are excited about the potential NDA filing with the FDA for Abuse Resistant Oxicontin. Controlled-release oxycodone drugs had U.S. sales of approximately $2 billion and IPCI's drug delivery platform, branded Rexista is a novel dosage form (paste in a capsule) designed to be deterrent to the well-documented abuses - including nasal inhalation when crushed or powdered, and by injection when combined with solvents. In May the company advised investors that it had taken delivery of and fully qualified its primary manufacturing equipment for the manufacture of the abuse-deterrent formulation and that the manufacture of clinical batches using that equipment had commenced. It is worth noting that the company's Rexista technology is applicable to additional opioid drug candidates like oxymorphone, hydrocodone, and morphine. As the technical analysis chart shows, the stock is primed to continue running higher- especially when you consider that prices are now within acceptable ranges for institutional investors and funds who may have been either hesitant or simply unwilling to jump in previously.

[postcard]

Thanks for the information on IPCI last week.
After revieewing the information it does have growth within the near future.
Will continue to watch..

[BiotechMaster]

Perfect time to get in.. There is huge support at current level .It will be too late to buy IPCI after new Partnership or FDA approval .GL


IPCI: Now has five ANDAs awaiting FDA approval
Monday, 04 April 2011 06:10


Intellipharmaceutics (Nasdaq:IPCI), one of the biotech companies whose future as both a near and long-term and investment we've been covering and following closely, today announced the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic of Seroquel XR®.

Seroquel XR® is an oral psychotropic agent indicated for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Sales of Seroquel XR® (quetiapine fumarate extended-release tablets) in the U.S. were approximately $823 million in 2010.

We expect the shares of this very low-float stock will move on this news alone, much less with news about any of the five ANDAs awaiting FDA approval. The reported sales for branded and generic versions of those pending approval products came in at approximately $8 billion in 2010. IPCI develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.

"The filing of a generic version of Seroquel XR® is one of the Company's performance milestones for 2011 and another important addition to our product portfolio filed for approval with the FDA, which includes generics of Focalin XR®, Effexor XR®, Protonix® DR and Glucophage® XR," commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "These filings not only provide further validation of our Hypermatrix™ technology, they clearly demonstrate the flexibility of our technology to efficiently and effectively match a number of drug delivery profiles."

Intellipharmaceutics now has five ANDAs awaiting FDA approval with reported sales for branded and generic versions of these products being approximately $8 billion in 2010. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.

[BiotechMaster]

The investors still not realise the real Value of this MEGA News from December . Protonix alone could make IPCI profitable and there are still many Drugs awaiting FDA approval . IPCI is very very Cheap but not for long thats for sure .GL
---

On December 22, 2010, IPCI announced that it had not been notified by Wyeth Pharmaceuticals of any patent infringement proceedings relating to IPCI’s application to market a generic version of Wyeth’s Protonix® (delayed-release pantoprazole sodium) tablets. To IPCI’s knowledge, Wyeth has not filed a patent infringement action within the 45 day period prescribed by law.

As a result, Intellipharmaceutics will not be subject to the automatic 30-month stay of FDA approval to market the product and should be in a position to market generic delayed-release pantoprazole sodium in the US upon its approval by the FDA.

If the release is not subject to a 30-month stay, the product could potentially be launched by early 2012. As this product could, by our estimates, account for more than $100 million for IPCI, its earlier commercialization should give the stock’s valuation a significant lift.

[madswa]

On March 29, 2011, Intellipharmaceutics announced that it had become aware that Elan Corporation, plc and Elan Pharma International Ltd. had filed a Complaint against Intellipharmaceutics Corp., Intellipharmaceutics Ltd., and Par Pharmaceutical, Inc., Intellipharmaceutics' development and commercialization partner for generic Focalin XR®, for alleged patent infringement in the United States District Court for the District of Delaware, relating to Intellipharmaceutics' generic version of 30mg Focalin XR®. On April 5, 2011, the Company also announced that it had become aware that, Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma AG, had filed a Complaint against Intellipharmaceutics Corp. for alleged patent infringement in the United States District Court for the District of New Jersey, relating to Intellipharmaceutics' generic version of 30mg Focalin XR®. In view of the previous settlement related to the four dosage strengths, the Company believes it is reasonable to expect that the litigation relating to the 30mg strength could also be settled on terms satisfactory to the Company, although no assurance can be provided to this effect. Lawsuits such as these are an ordinary and expected part of the process of obtaining approval to commercialize a generic drug product in the United States. The Company remains confident that its generic version of 30mg Focalin XR® does not in any event infringe the patents in issue.

Intellipharmaceutics Announces First Quarter 2011 Results (Nasdaq:IPCI)

[BiotechMaster]

Volume and Chart means takeoff could start today . If we break and close above the 200-Day Moving-Average at 3.15$ then look out .gl
IPCI - SharpCharts Workbench - StockCharts.com

[BiotechMaster]

Read this new article and you will know why IPCI is a pure Goldmine .GL

CEO says multiple deals, FDA approvals and more filings are in the works
Thursday, 21 April 2011 01:02

http://******************/2011042166...the-works.html

[BiotechMaster]

The train leaving the station ..Load up the cheap shares while you still can . gl

[ljdavis]

Here we go.. touching 4.00 by week end?